<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03527069</url>
  </required_header>
  <id_info>
    <org_study_id>EMS0617-CIPROS</org_study_id>
    <nct_id>NCT03527069</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Cipros 10 Association on the Isolated Hypertriglyceridemia and Dyslipidemia Treatment</brief_title>
  <official_title>Phase III, National, Multicenter, Randomized, Double Blind Clinical Trial, to Evaluate the Efficacy and Safety of Cipros 10 Association on Dyslipidemia Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>EMS</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>EMS</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy of Cipros 10 association in the&#xD;
      treatment of Dyslipidemia Treatment&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 29, 2021</start_date>
  <completion_date type="Anticipated">December 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">July 30, 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Reduction of serum triglyceride levels measured between the first visit and last visit.</measure>
    <time_frame>12 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence and severity of adverse events recorded during the study.</measure>
    <time_frame>13 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">298</enrollment>
  <condition>Hypertriglyceridemia</condition>
  <condition>Dyslipidemia</condition>
  <arm_group>
    <arm_group_label>CIPROS 10</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The study is double-Masked, the patient wil take 2 tablets, as follow:&#xD;
1 tablet Cipros 10 association; and&#xD;
1 tablet crestor placebo Oral, once a day.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Crestor</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The study is double-Masked, the patient wil take 2 tablets, as follow:&#xD;
1 tablet Crestor 10mg; and&#xD;
1 tablet Cipros association placebo Oral, once a day.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cipros 10 association</intervention_name>
    <description>oral, once a day.</description>
    <arm_group_label>CIPROS 10</arm_group_label>
    <other_name>EMS association</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Crestor 10 mg</intervention_name>
    <description>oral, once a day.</description>
    <arm_group_label>Crestor</arm_group_label>
    <other_name>Rosuvastatin 10 mg</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Participants of both sexes, aged 18 years or more;&#xD;
&#xD;
          -  Participants with the diagnosis of Dyslipidemia presentinf low or intermediate&#xD;
             cardiovascular risk, according to the Brazilian Guidelines on Dyslipidemia and&#xD;
             Prevention of Atherosclerosis;&#xD;
&#xD;
          -  Signed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of familial hypercholesterolemia and other genetic diseases;&#xD;
&#xD;
          -  Using medications that may interfere with the metabolism or serum levels of&#xD;
             triglycerides;&#xD;
&#xD;
          -  Any clinical and laboratory findings that, in the judgment of the investigator, may&#xD;
             interfere with the safety of research participants;&#xD;
&#xD;
          -  Presence of concomitant cardiovascular disease, renal failure and hepatic Failure;&#xD;
&#xD;
          -  Decompensated diabetes;&#xD;
&#xD;
          -  Current smoking;&#xD;
&#xD;
          -  History hypersensitivity to the active ingredients used in the study;&#xD;
&#xD;
          -  Pregnancy or risk of pregnancy and lactating patients;&#xD;
&#xD;
          -  History of alcohol abuse or illicit drug use;&#xD;
&#xD;
          -  Participation in clinical trial in the year prior to this study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Monalisa F.B. Oliveira, MD</last_name>
    <phone>+551938879851</phone>
    <email>pesquisa.clinica@ncfarma.com.br</email>
  </overall_contact>
  <location>
    <facility>
      <name>Allergisa</name>
      <address>
        <city>Campinas</city>
        <state>SÃ£o Paulo</state>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mauro A Crippa, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>May 4, 2018</study_first_submitted>
  <study_first_submitted_qc>May 4, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">May 16, 2018</study_first_posted>
  <last_update_submitted>February 23, 2021</last_update_submitted>
  <last_update_submitted_qc>February 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dyslipidemias</mesh_term>
    <mesh_term>Hypertriglyceridemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rosuvastatin Calcium</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

